• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fortress Biotech Inc. (Amendment)

    2/14/24 4:51:41 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBIO alert in real time by email
    SC 13G/A 1 tm243309d3_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

     SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    Fortress Biotech, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    34960Q109 

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP NO. 34960Q109 Page 2 of 7

     

    CUSIP No.  34960Q109
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 372,562
    (7) Sole dispositive power 0
    (8) Shared dispositive power 372,562
    (9) Aggregate amount beneficially owned by each reporting person 372,562
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 4.2%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO. 34960Q109 Page 3 of 7

     

    CUSIP No.  34960Q109
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 372,562
    (7) Sole dispositive power 0
    (8) Shared dispositive power 372,562
    (9) Aggregate amount beneficially owned by each reporting person 372,562
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 4.2%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO. 34960Q109 Page 4 of 7

     

    CUSIP No.  34960Q109
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 372,562
    (7) Sole dispositive power 0
    (8) Shared dispositive power 372,562
    (9) Aggregate amount beneficially owned by each reporting person 372,562
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 4.2%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      Fortress Biotech, Inc. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      1111 KANE CONCOURSE SUITE 301, BAY HARBOR ISLANDS, FL 33154
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, $0.001 par value (the “Shares”).

     

     

     

     

    CUSIP NO. 34960Q109 Page 5 of 7

     

    Item 2(e).

    CUSIP Number:
     

     

    34960Q109

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2023, Nantahala may be deemed to be the beneficial owner of 372,562 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of 4.2% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10Q filed November 14, 2023, there were 8,942,751 Shares outstanding of the Common Stock of – as of September 30, 2023).

     

     

     

     

    CUSIP NO. 34960Q109 Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 372,562
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 372,562
     

     

    Each of Messrs. Harkey and Mack

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 372,562
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 372,562
           
    Item 5. Ownership of Five Percent or Less of a Class:
       
      The Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E). See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:
       

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP NO. 34960Q109 Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC
         
      By: /s/ Taki Vasilakis
      Taki Vasilakis
      Chief Compliance Officer
         
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
         
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $FBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FBIO

    DatePrice TargetRatingAnalyst
    3/15/2024$10.00Buy
    ROTH MKM
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $FBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Jin David was granted 5,000 shares, increasing direct ownership by 0.40% to 1,245,893 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      4/1/25 4:20:16 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lobell J Jay was granted 49,383 shares, increasing direct ownership by 43% to 165,075 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      1/3/25 4:28:30 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Klein Dov was granted 49,383 shares, increasing direct ownership by 92% to 102,783 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      1/3/25 4:20:17 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM resumed coverage on Fortress Biotech with a new price target

      ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00

      3/15/24 7:18:10 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Fortress Biotech with a new price target

      Ladenburg Thalmann initiated coverage of Fortress Biotech with a rating of Buy and set a new price target of $6.00

      8/4/22 7:17:35 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on Fortress Biotech with a new price target

      Roth Capital reiterated coverage of Fortress Biotech with a rating of Buy and set a new price target of $5.00 from $4.50 previously

      4/20/21 8:28:52 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

      MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following sessions at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference, taking place on Tuesday, May 13, 2025: 2:00 p.m. – 2:30 p.m. ET: Fireside Chat5:00 p.m. – 6:00 p.m. ET: Panel Presentation: Development Stage Companies – Where Do Royalty and Tech Platform Plays

      5/7/25 8:00:13 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

      WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the fiscal year ended December 31, 2024, and recent corporate updates. Recent Corporate Updates: In March 2025, Checkpoint announced that it entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sun Pharmaceutical Industries, Inc. ("Sun Pharma"), and a wholly owned subsidiary of Sun Pharma, with Checkpoint continuing as the surviving corporation of the transaction and a wholly owned subsidiary of Sun Pharma (the "Merger"). The total transaction value

      3/28/25 8:30:04 AM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

      FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approve

      3/26/25 4:01:00 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fortress Biotech Inc.

      SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

      10/25/24 10:15:19 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

      SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

      9/25/24 4:45:18 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Fortress Biotech Inc. (Amendment)

      SC 13G/A - Fortress Biotech, Inc. (0001429260) (Subject)

      2/14/24 4:51:41 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      9/25/24 4:45:04 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/15/24 4:05:14 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/12/24 8:42:21 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Fortress Biotech Inc.

      DEFA14A - Fortress Biotech, Inc. (0001429260) (Filer)

      4/28/25 4:15:14 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Fortress Biotech Inc.

      DEF 14A - Fortress Biotech, Inc. (0001429260) (Filer)

      4/28/25 4:05:24 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Fortress Biotech Inc.

      PRE 14A - Fortress Biotech, Inc. (0001429260) (Filer)

      4/18/25 2:48:35 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

      SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

      7/11/24 4:05:39 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

      SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief

      5/1/24 4:01:30 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care